

1

The European Association for Palliative Care (EAPC) Guidelines for Cancer Pain 2015 . What's new ?

Augusto Caraceni

Palliative Care, Pain Therapy and Rehabilitation National Cancer Institute of Milan Italy , Vice Chair EAPC Research Network, Professor of Palliative Medicine Norwegian University of Science and Technology NTNU, Trondheim Norway

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

2

Original version of WHO analgesic ladder 1982

Figure 1 - Analgesic Ladder

Nonnarcotic +/- Adjuvant

If pain persists or increases

Weak narcotic +/- nonnarcotic +/- Adjuvant

If pain persists or increases

Strong narcotic +/- nonnarcotic +/- Adjuvant

The four groups of drugs will now be discussed in detail:

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

3

Morphine in cancer pain: modes of administration

Expert Working Group of the European Association for Palliative Care

BMJ - 1996

Morphine and alternative opioids in cancer pain: the EAPC recommendations

Expert Working Group of the Research Network of the European Association for Palliative Care

BJC - 2001

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

4

Review

Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC

Augusto Caraceni, Douglas Clark, David Clark, Michael Fallon, Peter Gøtzsche, Hans-Henrik Hansen, Hans-Jürgen Hinz, Jürgen Kleber, Michael Kuczkowski, Michael Nauck, Alexander Pagan, Lutz Raab, Robert R. Reade, Peter S. Spencer, Patrick Stone, David Tuckwell, Gunderman, Gopalakrishnan, for the European Palliative Care Research Collaborators (EPCRC), on behalf of the European Association for Palliative Care (EAPC)

Here we provide the updated version of the guidelines of the European Association for Palliative Care (EAPC) on the use of opioids for the treatment of cancer pain. The update was undertaken by the European Palliative Care Research Collaborators. Previous EAPC guidelines were reviewed and compared with other currently available guidelines, and consensus recommendations were created by formal international expert panel. The content of the guidelines was defined according to several topics, each of which was assigned to collaborators who developed systematic literature reviews with a common methodology. The recommendations were developed by a writing committee that considered the evidence derived from the systematic reviews with the palliative clinicians in a co-authored process, and were endorsed by the EAPC Board of Directors. The guidelines are presented as a list of evidence-based recommendations developed according to the Grading of Recommendations Assessment, Development and Evaluation system.

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

5

2012 EAPC RECOMMENDATIONS distinctive features

- Evidence based: 18 systematic reviews (Palliative Medicine 2011)
- GRADE system
- Obtained through an international consensus
- Independence warranted by European funding and EAPC endorsement.
- To be used and adapted to local needs all over the world

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

6

GRADE principles

Study quality limitation RCTs	Quality of the evidence
<ul style="list-style-type: none"> • Lack of allocation concealment • Lack of blinding • Incomplete accounting of outcomes • Selective outcome reporting • Other : early stopping for benefit 	<ul style="list-style-type: none"> • Limitations • Imprecision • Inconsistency • Indirectness • Publication bias

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

7

Guidelines update process

- New topics will be added and appropriate PICO will be defined.
- The GRADE method will be followed
- The AGREE criteria will be pursued in order to ensure quality; in particular a wider involvement of other stakeholders will be used to contribute in the GL development.
- The guidelines will be updated regularly every 3/5 years

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

8

The EAPC pain guidelines 2015 This set of recommendations focus on opioid drugs were included in 2012 version and have been updated

- R 1: WHO Step II Opioids (M. Maltoni, D. Tassinari I)
- R 2: WHO Step III opioid of first choice (A. Pigni, A. Caraceni I)
- R 3: Opioid titration (P.Klepstad, N)
- R 4: The role of transdermal opioids (Maltoni, Tassinari I)
- R 5: The role of methadone (N.Cherny Is)
- R 6: Opioid switching (O.Dale N)
- R 7: Opioid relative analgesic potency (S. Mercadante I)
- R 8: Alternative systemic routes of opioid administration (Radbruch, D)
- R 9: Opioids for breakthrough/incident pain (J. Zeppetella UK)
- R10: Treatment of opioid-related emesis (M. Fallon UK)
- R11: Treatment of opioid-related constipation (P.Larkin IR, P.Stone UK)
- R12: Treatment of opioid related CNS symptoms (P.Stone UK)
- R13: Use of opioids in renal failure (M.Fallon UK)
- R14: Role of paracetamol and NSAIDs in addition to Step III opioids (M.Nabal, E)
- R15: Role of adjuvants drugs for neuropathic pain (M.Bennett UK)

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

9

The EAPC pain guidelines 2015 These topics were added ,systematic reviews performed , recommendations will be developed if appropriate

- Pain assessment and classification (AK Knudsen, N) *
- Steroids (Ø. Paulsen, N) *
- NSAID and paracetamo as Step I (Radbruch L, D)
- Ketamine (M. Bennett , UK)
- Tapentadol (A.Pigni, I) *
- Oxycodone and naloxone combination (A. Pigni, I) *
- Opioids toxic interferences (D. Faksvåg Haugen) *
- Bisphosphonates and denosumab for bone pain (Porta J, E) *
- Radiotherapy and radionuclides (L.Lozza , I, R. Habermas N)
- Invasive procedures and spinal administrations (Sjogren P, Kurita G, D, S.Mercadante P Klepstad) *

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

10

WHO STEP III OPIOID OF FIRST CHOICE (proposed new formulation)

The data show no important differences between morphine, oxycodone and hydromorphone given by the oral route and permit a **strong** recommendation that any one of these three drugs can be used as the first choice opioid for moderate to severe cancer pain.

Updated A. Pigni et al Milan

- Mercadante et al 2010
- Yu S et al 2014
- Riley J et al 2014
- Kamboj et al 2014

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

11

- Pain assessment and classification

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

12

Palliative Medicine 2009; 22: 295-308

Classification of pain in cancer patients – a systematic literature review

AK Knudsen Pain and Palliation Research Group and Department of Cancer Research and Molecular Medicine, Faculty of Medicine, NTNU, Trondheim University Hospital, Trondheim, Norway Pain and Palliation

Palliative Medicine 2009; 22: 895-903

Pain assessment tools in palliative care: an urgent need for consensus

MJ Hjertqvist Department of Oncology, Umeå University Hospital, Umeå, Pain and Palliation Research

Expert conference on cancer pain assessment and classification—the need for international consensus: working proposals on international standards

Steen Kaasa,^{1,2} Giovanni Apolone,³ Pål Klepstad,⁴ Jon Hilvand Loge,^{5,6} Marianne Jensen Hjertqvist,^{7,8} Oscar Cori,⁹ Florian Strasser,¹⁰ Tarja Heiskanen,¹¹ Massimo Costantini,¹² Vittoria Zagari,¹³ Margareta Groenewald,^{14,15} Robin Fainsinger,¹⁶ Mark P. Jensen,¹⁷ John T Farrar,¹⁸ Henry McDary,¹⁹ Nan E Rotrock,²⁰ James Cleary,²¹ Catherine Deguire,^{22,23} Augusto Caraceni,^{24,25} European Palliative Care Research Collaborative (EPCRC) and the European Association for Palliative Care Research Network (EAPC RN)

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

13

2015 Update Pain Assessment and Classification

Figure 1. WHOCC Step 1 of the ladder - Pain assessment

Figure 2. WHOCC Step 2 of the ladder - Pain classification

Knudsen AK, Yulan Lin, Marianne Jensen Hjermsstad, Barry Laird, Katrin Sigurdardottir

14

New formulations/drugs

- In adult patients with moderate to severe pain directly due to cancer, which is the evidence that oral **tapentadol** is better than placebo, or other oral/transdermal opioids in the management of pain?
- In adult patients with moderate to severe pain directly due to cancer, which is the evidence that the combination of **oxycodone with naloxone** is better than placebo, or other oral/transdermal opioids in the management of pain and/or constipation?

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

15

Tapentadol in cancer pain updated to february 2015

Author year	Study design	comparator	N patients enrolled analyzed
Imanaka K 2013	DB RCT	Oxycodone SR	343 (265)
Kress HG 2014	DB RCT enriched enrollment	Placebo (Oral Morphine)	218 (184) (100/83)
Imanaka K 2014	RCT open label	Oral Morphine	100
Wiffen et al 2015	Cochrane Review		

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

16

Kress et al 2014

- Enriched enrollment design
 - 622 enrolled
 - 505 randomized titration to effect with either Tapentadol (338) or Morphine (158)
 - 219 rerandomized to Tapentadol (106) or placebo (112). 109 continued on morphine
 - 95 completed treatment (4 weeks) with placebo and 89 with tapentadol
 - Tapentadol superior to placebo

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

17

Non inferiority of tapentadol (64.5 mg) versus oxycodone SR (13.8 mg) within 1 point pain intensity difference

Imanaka et al 2013

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

18

Tapentadol summary of available evidences

- 2 Double-blind controlled RCTs
- Superiority with placebo in one enriched -enrollment study of low quality
- Non inferiority with low dose Oxycodone in one study of moderate quality (significant attrition)
- No evidence from trials that it can cause less nausea/vomiting than morphine

Cochrane Implications for practice

- For people with cancer** There is little in this review to suggest that tapentadol should be considered above other opioids for the treatment of cancer-related pain in terms of benefits or of harms.
- For clinicians** Current policies on the use of opioids, particularly morphine, do not need to be amended.

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

19

Oxycodone/naloxone combinations

Author	Study design	Comparator	N patients included /analysed
Meissner W 2009	RCT DB	CR Oxycodone	202 non cancer
Ahmedzai S 2012	RCT DB	CR Oxycodone	185 cancer (133)

Maximum approved dose 80/40 mg /day

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

20

Oxy/naloxone summary of available evidences

- It reduces opioid induced constipation
- One RCT in cancer patients at mean doses of 46.6 (22.6 SD) mg of OXN and of 43.1 (19.1 SD) of CR Oxycodone it was non inferior to oxycodone with very narrow non inferiority bound (- 0.47)
- Its analgesic efficacy in opioid tolerant patients using higher doses and for longer periods of time is unknown
- Case reports of antagonism of opioid analgesia have been reported

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

21

Oxy/naloxone open questions

- Dose equivalent to about 60 mg of oral morphine (40 mg oxycodone) have been tested in one RCT in cancer pain and can be considered a 1st level of WHO Step III dose. What happens at higher doses up to 80 mg oxycodone ?
- In practice people combines oxycodone or other drugs with the highest doses of Oxy/Nal. What happens to overall opioid analgesia/tolerance ?
- What happens when switching from higher doses of Oxy/Nal to another opioid or parenteral morphine

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

22

Bisphosphonates and denosumab

- Josep Porta and collaborators
 - 1585 retrieved papers were screened
 - 1471 were discarded based on abstract review as ineligible
 - 106 were examined in full
 - 35 eligible papers

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

23

Role of Bisphosphonates and denosumab for bone cancer pain

Form the data available, we can conclude that the evidence of the analgesic role of BP and denosumab is weak, since more trials support the effect of BP and denosumab in preventing pain through the delay of bone painful events than producing an analgesic effect per se.

In terms of clinical recommendations, cancer patients with a long life expectancy (months to years) could benefit for the administration of BP or denosumab in terms of sparing painful events, but for patients with a shorter prognosis time to live (weeks or few months) the prescription of BP or denosumab can be seen at least controversial.

J. Porta and co. Conclusions from submitted review article

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

24

Role of steroids for cancer pain

- SYSTEMATIC REVIEW 2013
- CLINICAL TRIAL 2014
- UPDATE OF LITERATURE REVIEW
- COCHRANE REVIEW 2015

Ørnulf Paulsen



www.ntnu.no/prc European Palliative Care Research Centre (PRC)

25

Steroids conclusions

- Weak evidence for analgesic effect in the 1st week of treatment in two adequately designed trials
- One negative trial

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

26

Corticosteroid and cancer pain metanalysis (Haywood A et al 2015 Cochrane metanalysis)

Figure 4. Forest plot of pain at 1 week.

Study or Subgroup	Drug		Control		Weight	Mean Difference, IV, Random, 95% CI	Mean Difference, IV, Random, 95% CI
	Mean	SD	Mean	SD			
Boles 2012	1.6	0.7	1.2	0.9	6	28.1%	-1.40 (-3.17, 0.37)
Watts 1995	2.96	1.4	1.9	0.91	1.5	21.8%	-1.03 (-2.09, 0.02)
Yonemura/Hayashi 2012	3.95	2.00	4.3	0.91	2.9	41.1%	-0.35 (-1.28, 0.58)
Watts 2004	3.4	1.4	3.2	1.4	21	5.7%	-0.81 (-2.53, 1.76)
Watanabe 2007	2.1	1.0	2.2	1.0	21	17.0%	-0.12 (-0.92, 0.62)
Palsson 2014	3.4	1.06	3.6	1.03	32	18.2%	-0.20 (-1.04, 0.62)
Total (95% CI)	164		151		100.0%		-0.81 (-1.36, -0.26)

Heterogeneity: Tau² 0.21; I² 9.7%; H₂ 5.0 (P = 0.03); P = 43%
Test for overall effect: Z = 2.90 (P = 0.002)

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

27

Clinically significant drug–drug interactions involving opioid analgesics used for pain treatment in patients with cancer: a systematic review

- Cancer pain patients receiving opioids usually use multiple other drugs. A systematic review on drug-drug interactions (DDIs) involving opioids in cancer patients identified 32 published case reports and case series. Opioid DDIs caused respiratory depression, CNS toxicity (sedation, delirium, serotonergic symptoms, myoclonus, and extrapyramidal symptoms), ventricular arrhythmia and impaired pain control. The most common mechanisms eliciting DDIs were changed opioid metabolism due to the effect on **CYP3A4** activity, a combination of several drugs with sedative and respiratory depressant properties, and DDIs due to an effect on opioid, dopamine, cholinergic, and serotonin activity in the CNS. It is recommended to recognize the risk associated with certain combinations of drugs (i.e. voriconazole or rifampicin plus oxycodone or fentanyl), and to as a general rule reduce polypharmacy as much as possible.

A. Kotlinska-Lemieszke, P. Klepstad, D. Faksvåg Haugen
Drug Design Development Ther 2015

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

28

The evidence of neuraxial administration of analgesic for cancer-related pain : a systematic review

- Is the spinal administration of opioids superior to systemic opioids ?
– 1 RCT less side effects
- Is the coadministration of local anesthetics superior to only opioid administration ?
– 2 RCTs No evidence
- Is the coadministration of clonidine superior to only opioid administration ?
– 1 RCT better pain relief more hypotension with clonidine
- Is the administration of ziconotide superior to opioids ?
– 1 RCT vs placebo , CNS side effects

Kurita GP, Bentzen KS, Nordly M, Mercadante S, Klepstad P, Sjogren P
Acta Anaesthesiol Scand 2015

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

29

Recommendations working formulation

- Intrathecal morphine administration alone
– Indication for opioid responsive pain with excessive side effects from systemic analgesics
- Coadministration of intrathecal morphine and bupivacaine
– Indication for pain which is poorly responsive to systemic analgesics
- Intrathecal clonidine or ziconotide in combination with morphine
– No indication at the moment

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

30

Sympathetic blocks for visceral cancer pain management: as systematic review and EAPC recommendations

- 3 Moderate quality RCTs on celiac plexus alcohol neurolysis for pancreatic cancer pain
- One Cochrane Review 2011 (57 and 54 pts)
– Moderate level of evidence of reduction in pain and/or opioid consumption
– Inconsistency across studies about pain relief duration and timing of block
– Percutaneous, endoscopic and intraoperative techniques

Mercadante S, Klepstad P, Kurita GP, Sjogren P, Giarratano A
Clinical reviews in Oncology/Hematology 2015

www.ntnu.no/prc European Palliative Care Research Centre (PRC)



32

The evidence of peripheral nerve blocks for cancer-related pain : a systematic review

- No randomized trials only anecdotal reports

Klepstad P, Kurita GP, Mercadante S, Sjogren P 2015

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

33

Minimally invasive procedure for the management of vertebral bone pain due to cancer. The EAPC recommendations

- Radiofrequency -
- Kiphoplasty +
- Vertebroplasty -
- Cryoablation -

Mercadante S, Klepstad P, Kurita GP, Sjogren P, Pigni A, Caraceni A Acta Oncologica 2015

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

34

EAPC Guidelines : the role drugs for cancer pain treatment

IV SQ Morphine

TTS buprenorphine

TTS fentanyl

Morphine (Ox, Hy)

Tapentadol

Oxycodone/nalo

Codeine Tram.

?

NSAID Paracetamol

NSAIDs, Paracetamol, Antidepressants, Anticonvulsants, Steroids

www.ntnu.no/prc European Palliative Care Research Centre (PRC)

35

EAPC Guidelines for analgesic drugs only : a simplified vision

Parenteral IV SQ

Oral Morphine

NSAID Paracetamol

NSAID Paracetamol Antidepressants, Anticonvulsants, Steroids

History of cancer pain from onset to death

www.ntnu.no/prc European Palliative Care Research Centre (PRC)